Rafferty Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$232K Buy
68,672
+1,137
+2% +$5.15K ﹤0.01% 1059
2026
Q2
$314K Sell
67,535
-33,361
-33% -$180K ﹤0.01% 1001
2026
Q1
$579K Sell
100,896
-1,263
-1% -$8.95K ﹤0.01% 866
2025
Q4
$1.01M Buy
+102,159
New +$932K ﹤0.01% 796

Other funds holding LXEO

Rafferty Asset Management's LXEO Position: Q3 2026 in Review

Rafferty Asset Management increased its Lexeo Therapeutics (LXEO) stake by 1.7% in Q3 2026, buying an estimated $5.15K and bringing the position to 68,672 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Rafferty Asset Management first reported a position in LXEO in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.01M in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Rafferty Asset Management held 68,672 shares of Lexeo Therapeutics worth $232K as of Q3 2026.
  • Rafferty Asset Management bought 1,137 Lexeo Therapeutics shares in Q3 2026, an estimated $5.15K.
  • Lexeo Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #1059 holding.
  • Rafferty Asset Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Rafferty Asset Management's Lexeo Therapeutics position peaked at $1.01M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.